Diabetic Macular Edema (DME) Clinical Trial
— AMARONEOfficial title:
A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) EYE103 in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part two doses of EYE103 will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Status | Recruiting |
Enrollment | 92 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity - DME patients must be = 18 years of age, NVAMD patients must be = 50 years of age - Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced. - DME patients must have vision loss in the study eye - NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye Exclusion Criteria: - Be pregnant or breastfeeding - History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening - Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening - Any other condition except for DME or NVAMD or that could affect interpretation of study assessments |
Country | Name | City | State |
---|---|---|---|
Argentina | Caba, Argentina | Caba | |
Argentina | Ciudad Autonoma Buenos Aires | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Puerto Rico | Arecibo, PR | Arecibo | |
United Kingdom | London, England | London | England |
United Kingdom | London, UK | London | |
United States | Abilene, TX | Abilene | Texas |
United States | Amarillo, TX | Amarillo | Texas |
United States | Austin, TX | Austin | Texas |
United States | Bakersfield, CA | Bakersfield | California |
United States | Bellaire, TX | Bellaire | Texas |
United States | Colorado Springs, Colorado | Colorado Springs | Colorado |
United States | Dallas, TX | Dallas | Texas |
United States | Germantown, TN | Germantown | Tennessee |
United States | Hagerstown, MD | Hagerstown | Maryland |
United States | Katy, TX | Katy | Texas |
United States | Knoxville, TN | Knoxville | Tennessee |
United States | Lakewood, CO | Lakewood | Colorado |
United States | Lemont, NV | Lemont | Illinois |
United States | McAllen, TX | McAllen | Texas |
United States | Modesto, CA | Modesto | California |
United States | Mountain View, CA | Mountain View | California |
United States | Nashville, TN | Nashville | Tennessee |
United States | Phoenix, AZ | Phoenix | Arizona |
United States | Plano, TX | Plano | Texas |
United States | Pompano Beach | Pompano Beach | Florida |
United States | Reno, NV | Reno | Nevada |
United States | Round Rock, TX | Round Rock | Texas |
United States | Sacramento, CA | Sacramento | California |
United States | Sacramento, CA | Sacramento | California |
United States | San Antonio, TX | San Antonio | Texas |
United States | The Woodlands, TX | The Woodlands | Texas |
United States | West Columbia, SC | West Columbia | South Carolina |
Lead Sponsor | Collaborator |
---|---|
EyeBiotech Ltd. |
United States, Argentina, Puerto Rico, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | Adverse Events | 3 months | |
Secondary | Best-corrected Visual Acuity | Best-corrected Visual Acuity | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01702441 -
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04543331 -
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
|
||
Completed |
NCT02424019 -
Phase 4 IOP Signals Associated With ILUVIEN®
|
Phase 4 | |
Completed |
NCT02633852 -
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT04857996 -
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
|
Phase 2 | |
Completed |
NCT04739306 -
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
|
Phase 3 | |
Recruiting |
NCT06116916 -
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
|
Phase 2 | |
Completed |
NCT02050828 -
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
|
Phase 2 | |
Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A | |
Terminated |
NCT02080091 -
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
|
N/A | |
Terminated |
NCT04697758 -
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
Terminated |
NCT00936520 -
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
|
Phase 1 | |
Not yet recruiting |
NCT06398080 -
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
|
||
Active, not recruiting |
NCT05989126 -
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
|
Phase 3 |